These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 27664949)

  • 1. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
    Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
    Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
    Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
    Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
    Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
    Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α- Tocopherol succinate loaded nano-structed lipid carriers improves antitumor activity of doxorubicin in breast cancer models in vivo.
    Fernandes RS; Silva JO; Seabra HA; Oliveira MS; Carregal VM; Vilela JMC; Andrade MS; Townsend DM; Colletti PM; Leite EA; Cardoso VN; Ferreira LAM; Rubello D; Barros ALB
    Biomed Pharmacother; 2018 Jul; 103():1348-1354. PubMed ID: 29864917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
    Wong HL; Rauth AM; Bendayan R; Wu XY
    Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
    Zou Y; Meng F; Deng C; Zhong Z
    J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclareol is a potent enhancer of doxorubicin: Evaluation of the free combination and co-loaded nanostructured lipid carriers against breast cancer.
    Borges GSM; Silva JO; Fernandes RS; de Souza ÂM; Cassali GD; Yoshida MI; Leite EA; de Barros ALB; Ferreira LAM
    Life Sci; 2019 Sep; 232():116678. PubMed ID: 31344429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
    Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
    Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lipid composition on the properties of doxorubicin-loaded liposomes.
    Sakai-Kato K; Nanjo K; Kawanishi T; Okuda H; Goda Y
    Ther Deliv; 2015 Jul; 6(7):785-94. PubMed ID: 26228772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.
    Zhao C; Feng Q; Dou Z; Yuan W; Sui C; Zhang X; Xia G; Sun H; Ma J
    PLoS One; 2013; 8(9):e73860. PubMed ID: 24040096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
    Lages EB; Fernandes RS; Andrade MMS; Paiyabhroma N; de Oliveira RB; Fernandes C; Cassali GD; Sicard P; Richard S; Branco de Barros AL; Ferreira LAM
    Biomed Pharmacother; 2021 Dec; 144():112373. PubMed ID: 34794238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.
    Abdolahpour S; Toliyat T; Omidfar K; Modjtahedi H; Wong AJ; Rasaee MJ; Kashanian S; Paknejad M
    Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):89-94. PubMed ID: 28296511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.
    Xiao W; Chen X; Yang L; Mao Y; Wei Y; Chen L
    Int J Pharm; 2010 Jun; 393(1-2):119-26. PubMed ID: 20416367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of antitumor effect of doxorubicin by its complexation with gamma-cyclodextrin in pegylated liposomes.
    Arima H; Hagiwara Y; Hirayama F; Uekama K
    J Drug Target; 2006 May; 14(4):225-32. PubMed ID: 16777681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
    Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
    Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?
    Du J; Li L
    Drug Deliv; 2016 Jun; 23(5):1799-809. PubMed ID: 26455787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.